Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Waters

Showing results (81-90 of 134) with videos related to

Pageof 14
Sort By:
Journal of Multimorbidity and Comorbidity|April 7, 2025
Multimorbidity frameworks impact the composition of patterns and their associations with patient-reported outcomes among people with HIVLuxsena Sukumaran, Alan Winston, Jane Anderson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2008
Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in UgandaLaura Waters, Andrew Kambugu, Hilda Tibenderana, et al.
AIDS (London, England)|June 6, 2025
Changes in multimorbidity burden and their impact on patient and healthcare outcomes in people with HIV over a 3-5-year periodLuxsena Sukumaran, Alan Winston, Frank A Post, et al.
Clinical Pharmacology and Therapeutics|May 14, 2022
Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and ComedicationsCatia Marzolini, Daniel R Kuritzkes, Fiona Marra, et al.
Virology Journal|February 10, 2025
Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance- a phase IV randomised, open-label study (PIBIK study)Collins Iwuji, Laura Waters, Ana Milinkovic, et al.
AIDS (London, England)|October 1, 2019
No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIVJames E Burns, Oliver T Stirrup, David Dunn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 19, 2025
Hepatitis B reactivation following switch away from tenofovir-containing anti-retroviral therapy in people living with HIV: A case series and lessons for practiceFlora Olcott, Philip D Oddie, Maeve J Barlow, et al.
AIDS (London, England)|December 30, 2025
Associations between plasma biomarkers and changes in cognitive function over two years in people with and without HIVJasmini Alagaratnam, Nicholas Bakewell, Ken M Kunisaki, et al.
HIV Medicine|March 19, 2026
Missed opportunities to prevent HIV acquisition with pre-exposure prophylaxis: A mixed methods study of people with recently acquired HIV in the United KingdomArgyro Karakosta, Emily Jay Nicholls, Flavien Coukan, et al.
The Lancet. Infectious Diseases|July 9, 2022
Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021-22: a descriptive epidemiological studyHannah Charles, Mateo Prochazka, Katie Thorley, et al.
Pageof 14

Showing results (81-90 of 134) with videos related to

Sort By:
Pageof 14
Journal of Multimorbidity and Comorbidity|April 7, 2025
Multimorbidity frameworks impact the composition of patterns and their associations with patient-reported outcomes among people with HIVLuxsena Sukumaran, Alan Winston, Jane Anderson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2008
Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in UgandaLaura Waters, Andrew Kambugu, Hilda Tibenderana, et al.
AIDS (London, England)|June 6, 2025
Changes in multimorbidity burden and their impact on patient and healthcare outcomes in people with HIV over a 3-5-year periodLuxsena Sukumaran, Alan Winston, Frank A Post, et al.
Clinical Pharmacology and Therapeutics|May 14, 2022
Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and ComedicationsCatia Marzolini, Daniel R Kuritzkes, Fiona Marra, et al.
Virology Journal|February 10, 2025
Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance- a phase IV randomised, open-label study (PIBIK study)Collins Iwuji, Laura Waters, Ana Milinkovic, et al.
AIDS (London, England)|October 1, 2019
No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIVJames E Burns, Oliver T Stirrup, David Dunn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 19, 2025
Hepatitis B reactivation following switch away from tenofovir-containing anti-retroviral therapy in people living with HIV: A case series and lessons for practiceFlora Olcott, Philip D Oddie, Maeve J Barlow, et al.
AIDS (London, England)|December 30, 2025
Associations between plasma biomarkers and changes in cognitive function over two years in people with and without HIVJasmini Alagaratnam, Nicholas Bakewell, Ken M Kunisaki, et al.
HIV Medicine|March 19, 2026
Missed opportunities to prevent HIV acquisition with pre-exposure prophylaxis: A mixed methods study of people with recently acquired HIV in the United KingdomArgyro Karakosta, Emily Jay Nicholls, Flavien Coukan, et al.
The Lancet. Infectious Diseases|July 9, 2022
Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021-22: a descriptive epidemiological studyHannah Charles, Mateo Prochazka, Katie Thorley, et al.
Pageof 14